Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)-Reference-Cited by-同舟云学术

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Published:2019-06 Issue:6 Volume:14 Page:1086-1094
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dziadziuszko Rafal,Smit Egbert F.,Dafni Urania,Wolf Juergen,Wasąg Bartosz,Biernat Wojciech,Finn Stephen P.,Kammler Roswitha,Tsourti Zoi,Rabaglio Manuela,Ruepp Barbara^ORCID,Roschitzki-Voser Heidi^ORCID,Stahel Rolf A.,Felip Enriqueta,Peters Solange

Funder

Roche

Bristol-Myers Squibb

Novartis

Pfizer

Genentech

Amgen

Hoffman-La Roche

Illumina

Merck Sharp & Dohme

Merck

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas;Shigematsu;Cancer Res,2005

2. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas;Arcila;Clin Cancer Res,2012

3. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy;Perera;Proc Natl Acad Sci U S A,2009

4. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project;Blackhall;J Clin Oncol,2014

5. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers;Tomizawa;Lung Cancer,2011

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer;Biochemical and Biophysical Research Communications;2024-09

2. Afatinib in Advanced Lung Squamous Cancer Harboring HER2 Mutation in Exon 17 Plus Amplification;American Journal of Therapeutics;2024-09

3. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review;ecancermedicalscience;2024-08-01

4. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study;Discover Oncology;2024-07-16

5. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study;Signal Transduction and Targeted Therapy;2024-07-15